Share your experience: Join a U.S. follicular lymphoma patient survey
Living with follicular lymphoma or indolent NHL in the U.S.? Take our 20-minute survey to share your treatment experiences and preferences. Your input will support research and patient-focused programs.
Highlights from our satellite symposium “Charting our Progress Towards a Cure”
At the recent 18th International Conference on Malignant Lymphoma (ICML), the FLF shone a spotlight on follicular lymphoma by hosting our very own satellite symposium for the second time, titled: “Charting our Progress Towards a Cure”. Read more to find out the key takeaways and highlights from the symposium.
Tafasitamab Treatment Option Approved for Relapsed or Refractory Follicular Lymphoma in US
In June 2025, the U.S. Food and Drug Administration (FDA) approved a new combination treatment option for adults with relapsed or refractory follicular lymphoma (FL).
This combination includes tafasitamab (also known as Monjuvi®, developed by Incyte), rituximab, and lenalidomide — and is now available for eligible patients in the United States.
The Power of Seed Funding: Accelerating Research in Follicular Lymphoma
One example of the impactful ways we advance our mission to cure follicular lymphoma (FL) is through our seed funding of the world-renowned Dana-Farber Cancer Institute.
FLF shines a spotlight on follicular lymphoma at 18-ICML
We are thrilled to announce that the FLF will be taking centre stage at the upcoming 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, from June 17th-21st, 2025.
Driving Breakthroughs in Follicular Lymphoma Research
At the Follicular Lymphoma Foundation (FLF), we’re funding bold, high-impact research to transform what it means to live with follicular lymphoma (FL). Guided by ongoing input from patients, we’re focused on accelerating progress toward cure.
Liso-Cel CAR-T cell therapy approved for relapsed/refractory follicular lymphoma in the EU and UK
In recent weeks there have been a number of announcements regarding an alternative treatment option now being available for adults with relapsed/ refractory indolent follicular lymphoma (FL) across the EU and transformed follicular lymphoma within the UK.
Two new ASPIRE awards target Biomarker Discovery in Follicular Lymphoma
The Mark Foundation for Cancer Research and the Follicular Lymphoma Foundation have joined forces to co-fund two new ASPIRE Awards focused on developing more personalized treatment strategies for FL.
Insights and Impact: The FLF at ASH Annual Meeting 2024, San Diego
The Follicular Lymphoma Foundation (FLF) was thrilled to participate in the recent American Society of Hematology (ASH) Annual Meeting.
Welcoming Emma France as FLF’s New Global CEO
The FLF welcomes Emma France as our new Global CEO. With over 20 years of non-profit leadership, Emma will help drive our mission forward with bold action and impactful change.